Home > Haematology > EBMT 2023 > EBMT 2023 Highlights Podcast

EBMT 2023 Highlights Podcast

Presented By
Robert van den Heuvel, Medicom
EBMT 2023

In this episode, Medicom’s correspondent covers 6 presentations from the annual meeting of the European Society for Blood and Marrow Transplantation (EBMT 2023), held in Paris, France, from 23-26 April 2023.
The topics discussed are:

  1. Ide-cel superior to standard therapies in triple-class-exposed RRMM
    Idecabtagene vicleucel (ide-cel) outperformed standard regimens in patients with triple class-exposed relapsed and refractory multiple myeloma. The results of the phase 3 KarMMa-3 study supported the use of ide-cel in this hard-to-treat population.
  2. Blinatumomab may improve outcomes in patients with B-cell ALL undergoing ASCT
    In a retrospective study, pre-transplantation blinatumomab was linked to better overall survival and reduced treatment-related mortality in patients with B-cell acute lymphoblastic leukaemia undergoing allogeneic stem cell transplantation.
  3. Quizartinib provides benefits on top of ASCT in AML
    In patients with newly diagnosed acute myeloid leukaemia with FLT3 internal tandem duplication, additional quizartinib, on top of standard induction and consolidation therapy, improved overall survival in the phase 3 QuANTUM-First trial. Moreover, in the subset of patients who underwent allogeneic stem cell transplantation in first clinical remission, quizartinib still resulted in significant overall survival improvement.
  4. Long-term success for CD19 CAR T-cell therapy in CLL
    CAR T-cell therapy may be a solution for a subset of patients with heavily pre-treated, high-risk, ibrutinib-intolerant, relapsed or refractory chronic lymphocytic leukaemia, as shown by long-term follow-up data of a phase 2 trial.
  5. Tacrolimus versus cyclosporine A in AML
    In patients with acute myeloid leukaemia who are in first complete remission undergoing T-cell replete haematopoietic cell transplantation with either haploidentical or unrelated donors, tacrolimus or cyclosporine A combined with post-transplantation cyclophosphamide (PT-Cy) and mycophenolate mofetil (MMF) resulted in similar overall survival and graft-versus-host disease (GvHD)-free, relapse-free survival outcomes. However, tacrolimus was associated with a decreased risk of acute GvHD compared with cyclosporine A in the subset of patients with haploidentical donors.
  6. Can molecular data improve prognostication in MDS patients undergoing HSCT?
    In the prognostication of patients with myelodysplastic syndromes (MDS) undergoing hematopoietic stem cell transplant (HSCT), findings from a large, international study showed that molecular data improved the prediction of overall survival (OS) modestly.

Enjoy listening!
Copyright ©2023 Medicom Medical Publishers

Posted on